Concepedia

Author

Wendy Halpern

Human Genome Sciences (United States)ORCID

Also Known As

Shuo Xiao, W Halpern, W. Halpern, Wendy G Halpern, Wendy G. Halpern, Wendy Green Halpern, Wendy Halpern

63

Publications

2.5K

Citations

19

H-Index

73

Concepts

All Affiliations

Human Genome Sciences (United States)Amgen (United States)Eli Lilly (United States)Research Triangle Park FoundationUnited States Food and Drug Administration
WH

About

Wendy Halpern is an author at Human Genome Sciences (United States) specializing in medicine, immunology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

694

2

Public Health

3

3

74

3

Cell Biology

3

3

146

4

Allergy

1

1

98

5

Cellular Physiology

1

1

24

Wendy Halpern

×

18

Publications

2.3K

Citations

15

H-Index

YearCitations

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

Kevin P. Baker, Bryan Edwards, Sarah Main,

Arthritis & Rheumatism

2003

470

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Anthony W. Tolcher, Monica Mita, Neal J. Meropol,

Journal of Clinical Oncology

2007

311

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

Ruth Plummer, Gerhardt Attard, Simon Pacey,

Clinical Cancer Research

2007

243

Use of Severity Grades to Characterize Histopathologic Changes

Kenneth A. Schafer, John Eighmy, James Fikes,

Toxicologic Pathology

2018

201

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

F. Anthony Greco, Philip Bonomi, Jeffrey Crawford,

Lung Cancer

2008

163

Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects

Wendy Halpern, Patrick B. Lappin, Thomas A. Zanardi,

Toxicological Sciences

2006

148

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

Anas Younes, Julie M. Vose, Andrew D. Zelenetz,

British Journal of Cancer

2010

129

Retrospective analysis of implant survival and the influence of periodontal disease and immediate placement on long-term results.

Cyril I. Evian, R C Emling, Edwin S. Rosenberg,

PubMed

2004

116

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice

Robert J. Melder, Blaire L. Osborn, Todd Riccobene,

Cancer Immunology Immunotherapy

2004

111

Use of Tissue Cross-reactivity Studies in the Development of Antibody-based Biopharmaceuticals

Michael W. Leach, Wendy Halpern, Carol W. Johnson,

Toxicologic Pathology

2010

98

Page 1